-transparent.png){kind=logo}
1,25-Dihydroxyvitamin D3 receptors are cytosoluble proteins detectable in a variety of tissues responsive to 1,25(OH)2D3. They are DNA binding-proteins analogous to other steroid receptors and it is this functional property which is likely involved in the activation of hormone-sensitive genes. Utilizing 1,25(OH)2D3 and DNA binding assays, as well as anti-receptor monoclonal antibodies, we have probed the relationship between the 1,25(OH)2D3 receptor binding domains after selective cleavage with trypsin. These studies reveal that the hormone and DNA binding regions are separable, and are consistent with the finding that tissue resistance to 1,25(OH)2D3 is a result of structural defects in these domains. Recently, a primate model, the LLC-MK2 monkey kidney line, has been uncovered which may exemplify a hormone-binding defect. Here, 25-hydroxyvitamin D3-24-hydroxylase induction, a 1,25(OH)2D3 bioresponse, requires 100-fold higher concentrations of the hormone for maximal response. Concomitantly, this cell contains a variant receptor form which displays a correspondingly lowered apparent affinity for the hormone despite its seemingly normal DNA binding characteristics. Taken together, these studies suggest that the 1,25(OH)2D3 receptor is a macromolecule with multiple domains each of which may produce modified cellular resistance to 1,25(OH)2D3 if structurally altered.
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
October 1989,
Biokhimiia (Moscow, Russia),
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
January 1989,
Archives of biochemistry and biophysics,
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
May 1984,
Science (New York, N.Y.),
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
April 1990,
Nutrition reviews,
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
December 1989,
The Journal of biological chemistry,
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
March 2013,
The Journal of clinical endocrinology and metabolism,
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
April 1980,
Lancet (London, England),
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
May 1980,
Lancet (London, England),
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
April 1981,
Journal of steroid biochemistry,
J W Pike, and
E A Allegretto, and
M A Kelly, and
C A Donaldson, and
S L Marion, and
D J Mangelsdorf, and
M R Haussler
September 1983,
Science (New York, N.Y.),
